SOX30-mediated activation of CXCL2 as promotor of PMN-MDSC recruitment and immunosuppressive microenvironment in TNBC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results